1. Home
  2. PDSB vs GBIO Comparison

PDSB vs GBIO Comparison

Compare PDSB & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PDSB
  • GBIO
  • Stock Information
  • Founded
  • PDSB 2005
  • GBIO 2016
  • Country
  • PDSB United States
  • GBIO United States
  • Employees
  • PDSB N/A
  • GBIO N/A
  • Industry
  • PDSB Biotechnology: Pharmaceutical Preparations
  • GBIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • PDSB Health Care
  • GBIO Health Care
  • Exchange
  • PDSB Nasdaq
  • GBIO Nasdaq
  • Market Cap
  • PDSB 44.5M
  • GBIO 41.2M
  • IPO Year
  • PDSB N/A
  • GBIO 2020
  • Fundamental
  • Price
  • PDSB $0.94
  • GBIO $6.12
  • Analyst Decision
  • PDSB Strong Buy
  • GBIO Buy
  • Analyst Count
  • PDSB 2
  • GBIO 4
  • Target Price
  • PDSB $10.00
  • GBIO $10.67
  • AVG Volume (30 Days)
  • PDSB 489.6K
  • GBIO 44.8K
  • Earning Date
  • PDSB 11-13-2025
  • GBIO 11-10-2025
  • Dividend Yield
  • PDSB N/A
  • GBIO N/A
  • EPS Growth
  • PDSB N/A
  • GBIO N/A
  • EPS
  • PDSB N/A
  • GBIO N/A
  • Revenue
  • PDSB N/A
  • GBIO $21,230,000.00
  • Revenue This Year
  • PDSB N/A
  • GBIO N/A
  • Revenue Next Year
  • PDSB N/A
  • GBIO N/A
  • P/E Ratio
  • PDSB N/A
  • GBIO N/A
  • Revenue Growth
  • PDSB N/A
  • GBIO 61.15
  • 52 Week Low
  • PDSB $0.85
  • GBIO $3.00
  • 52 Week High
  • PDSB $3.48
  • GBIO $25.70
  • Technical
  • Relative Strength Index (RSI)
  • PDSB 40.57
  • GBIO 50.24
  • Support Level
  • PDSB $0.89
  • GBIO $6.06
  • Resistance Level
  • PDSB $1.03
  • GBIO $6.47
  • Average True Range (ATR)
  • PDSB 0.06
  • GBIO 0.31
  • MACD
  • PDSB 0.00
  • GBIO -0.07
  • Stochastic Oscillator
  • PDSB 31.67
  • GBIO 16.15

About PDSB PDS Biotechnology Corporation

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Share on Social Networks: